LB-208, LB-208 clinical trials

Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

This study is looking at a new medicine, LB-208, for adults with specific types of leukaemia (AML) and myelodysplastic syndrome (MDS) that have come back or not responded to treatment. It aims to check the safety of LB-208 and how well it works.